Viracta Therapeutics Financials

Viracta Therapeutics Stock Summary

Viracta Therapeutics competes with Vincerx Pharma, Rallybio Corp, Tenaya Therapeutics, Lyra Therapeutics, and Trevi Therapeutics. Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.

Viracta Therapeutics Key Financial Ratios

Viracta Therapeutics' financial ratios allow both analysts and investors to convert raw data from Viracta Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Viracta Therapeutics over time and compare it to other companies across industries.

Viracta Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Viracta Therapeutics's current stock value. Our valuation model uses many indicators to compare Viracta Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viracta Therapeutics competition to find correlations between indicators driving Viracta Therapeutics's intrinsic value. More Info.Viracta Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Viracta Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Viracta Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Viracta Therapeutics Market Pulse

Along with financial statement analysis, the daily predictive indicators of Viracta Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Viracta Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Viracta Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Viracta Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Viracta Therapeutics's daily price indicators and compare them against related drivers.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

If you are still planning to invest in Viracta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viracta Therapeutics' history and understand the potential risks before investing.